Business Wire

FUJIFILM Corporation Announces Results from Phase II Clinical Trial of "T-817MA" in Patients with Alzheimer's Disease in the United States

Jaa

FUJIFILM Corporation (TOKYO: 4901) (President: Kenji Sukeno) announced that the company’s Alzheimer’s Disease drug “T-817MA,” did not meet its primary study endpoints of cognition or global clinical function in its Phase II clinical trial conducted in the United States on patients with mild to moderate Alzheimer’s Disease (AD). There were no significant differences in secondary outcomes. In exploratory analyses, change of the cerebrospinal fluid (CSF) biomarker phospho-tau (p-Tau) benefited from the higher dose treatment while hippocampal*1 volumes decreased less in the lower doses group with statistical significance. Post hoc analyses also suggested T-817MA treatment with shorter duration of illness and symptoms was associated with better cognitive outcomes with statistical significance. Fujifilm will review the results of the Phase II clinical trial with regulatory authorities including FDA (U.S. Food and Drug Administration) and will take necessary steps toward further development including Phase III clinical trial of this compound.

A pre-clinical research, led by Dr. Rudolph Tanzi, Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School, and Vice-Chair of Neurology at Massachusetts General Hospital, revealed that T-817MA acts on microglia*2 that have a risk gene for AD and promotes the clearance of amyloid-β (Aβ).
These results suggest that T-817MA may act on p-Tau and Aβ, major causal substances in AD.

AD’s main symptoms are abnormalities in cognitive functions, including memory. It is believed that abnormality of neurological functions in AD manifests as a result of Aβ protein deposits (senile plaques) in the brain. The progression of the disease has strong association with the formation of abnormal assemblies caused by hyperphosphorylation and fibrillization of tau proteins, found in the axons of nerve cells (neurofibrillary tangle), synapse*3 loss and atrophy of the brain including hippocampus.
The number of people suffering from dementia is estimated to be 44 million around the world. The number is projected to increase to 76 million by 2030 with the aging of the world population. Over half of these dementia cases suffer from AD, and the trend is set to continue.
AD drugs currently available on the market include acetylcholinesterase inhibitors, such as donepezil hydrochloride. As these drugs address the deficit in neurotransmission to give temporary improvement to the patients' symptoms, there is an unmet need for a new class of therapies to treat AD.

T-817MA is an AD drug discovered by the Fujifilm Group company, Toyama Chemical. It has potent neuroprotective effect and promotes neurite outgrowth through the activation of sigma receptors*4, demonstrating strong efficacy in animal models. Fujifilm is committed to further accelerating the development of T-817MA under possible partnerships, and contributing to resolving social challenges through the delivery of innovative pharmaceutical products.

 
  *1   Hippocampus is a region of the cerebrum, associated with memory. AD causes neuronal loss, which results in hippocampal atrophy.
*2 Microglia are a type of glia cells, which are component of the central nervous system. Microglia provide immune defense in the brain, while also being involved in repairing abnormal neural cells, and eliminating the aggregated Aβ. At the same time, excessively activated microglia are known to play a role in neuro-degeneration in the central nervous system.
*3 Synapse is a structure connecting neurons, allowing them to pass electrical signals to convey information between them.
*4 Sigma receptors are protein that exists on the membrane of endoplasmic reticulum in cells, and have the function of mitigating neuro-degeneration in the central nervous system.
 

Contact information

For enquiries on information in this media release, contact:
Media contact
FUJIFILM Corporation
Kana Matsumoto, +81 3-6271-2000
Corporate Communications Division
Other
FUJIFILM Corporation
Pharmaceutical Products Division
TEL +81 3-6271-2171

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

HCL Technologies Powers Volvo Ocean Race 2017-1823.10.2017 16:02Tiedote

The 2017-18 edition of the Volvo Ocean Race was flagged off at Alicante, Spain, with HCL Technologies as the strategic IT services provider. The leading global IT services company has provided end-to-end infrastructure support as well as connectivity between the Race Village and the Command Centre in Alicante further connecting them to 12 Host Cities on the race route globally. The world's longest and toughest professional sporting event began at Alicante and will finish eight months later at The Hague. At the flag-off, Jordi Neves, Chief Digital Officer, Volvo Ocean Race, said: “Over four decades, Volvo Ocean Race has drawn some of the greatest ever sailors. This edition of the race will be more digitally focused than before, with HCL as the strategic IT services provider. This edition is also special for us as we embark on a major Sustainability Program in partnership wi

CES Unveiled Paris Returns Tomorrow for Fifth Year with 70+ Exhibitors23.10.2017 16:00Tiedote

Consumer Technology Association (CTA):   WHAT:             CES Unveiled Paris returns to Paris tomorrow, for its fifth consecutive year, hosting more than 70 exhibitors. More than 600 attendees are expected at the event which will unite French tech startups, top media, buyers and industry influencers around the latest tech innovation and provide a preview of CES® 2018. Schedule as follows:  

Wipro Cited as a Leader in Everest Group PEAK Matrix™ for IT Security Services23.10.2017 15:59Tiedote

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has been recognized as a ‘Leader’ by Everest Group, a global independent consulting and research firm, in its report titled “IT Security Services- Market Trends and PEAK MatrixTM Assessment 2017: Security- the Biggest Digital Insecurity”. The report analyzed the capabilities of 17 leading global IT service providers on Everest Group’s PEAK Matrix. Wipro has been named as a Leader for its strong global delivery network with a transformational mind-set, and its ability to deliver high quality of services across regions and service segments, in terms of both execution and responsiveness. The report highlights the trends influencing the IT security services market, focusing on the increasing complexities, size and

ZeroStack Delivers Unified Multi-Cloud Application Development Platform Leveraging Existing Hardware Assets23.10.2017 15:00Tiedote

ZeroStack, Inc., creators of the self-driving on-premises cloud, today announced that its cloud platform now runs on Nutanix HCI hardware, expanding choices for IT departments that want to empower their DevOps groups with a software-defined infrastructure that offers SaaS-delivered, multi-cloud operations. Developers can have a consistent platform no matter where they are located while reducing operational complexity and costs. Developers need a common platform to reduce costs and ensure efficient processes for software development, and budget-constrained IT departments want to gain maximum leverage out of existing hardware. ZeroStack’s Intelligent Cloud Platform is hardware independent, so it enables consistent processes regardless of the hardware used or where the developers access the infrastructure. As a result, developers can create secure private workspaces and build a per

Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab23.10.2017 14:15Tiedote

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today that the companies have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer’s disease treatments. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171023005462/en/ Under the terms of the agreement Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen’s investigational anti-amyloid beta (Aβ) antibody for patients with Alzheimer’s disease (“AD”). The expanded agreement leverages each company’s respective geographic strengths for commercialization and adjusts the respective share of profits from potential sales of aducanumab. Biogen will receive 55

Open Letter from Mats Granryd, Director General, GSMA23.10.2017 14:01Tiedote

Dear Ministers, As you are no doubt aware, European citizens and businesses rely on mobile networks to socialise, do business and access information everyday in every corner of every Member State of the Union. The social and economic activity that rides over this digital infrastructure drives economic growth, shapes future innovation and fosters more inclusive societies. As you prepare to convene at tomorrow’s Ministerial Council Meeting, I must express my grave concerns on the current state of discussions on the proposed European Electronic Communication Code (the Code). Although the European Union’s vision of a ‘Gigabit Society’, and recent discussions amongst the European Heads of State, demonstrate a strong ambition to recapture the region’s digital leadership and harness the full power of digital to drive growth, jobs and competitiveness, we do not see action foc

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme